Professional background

Dr Priftakis has been a member of the medical team at the Institute of Nuclear Medicine since 2018.

His clinical practice includes a wide range of isotope-based imaging and therapeutic applications.

Key interests: myocardial perfusion imaging with Rubidium-82 PET, imaging for assessment of response to cancer treatment, PET-based radiotherapy planning, targeted molecular radiotherapy in thyroid cancer and other rare cancers.


Research interests

PSMA tracers for prostate cancer

Clinical utility of PET-derived quantitative parameters

Languages spoken



Imaging of Prostate Cancer Recurrence in the Vas Deferens With 68Ga-PSMA PET/CT.Priftakis D, Afaq A, Bomanji J. Clin Nucl Med. 2020 Jan;45(1):49-51.

The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas.Skoura E, Priftakis D, Novruzov F, Caplin ME, Gnanasegaran G, Navalkissoor S, Bomanji J. Nucl Med Commun. 2020 Feb;41(2):169-174.

Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis.Priftakis D, Riaz S, Zumla A, Bomanji J. Int J Infect Dis. 2020 Mar;92S:S85-S90.

COVID-19 in the act: incidental 18F-FDG PET/CT findings in asymptomatic patients and those with symptoms not primarily correlated with COVID-19 during the United Kingdom coronavirus lockdown.Halsey R, Priftakis D, Mackenzie S, Wan S, Davis LM, Lilburn D, Thornton A, Papathanasiou N, Gnanasegaran G, Bomanji J. Eur J Nucl Med Mol Imaging. 2020 Aug 5:1-13.